Brought to you by 
Public offering nets $325mm for Clovis Oncology
29 Jun 2017
Executive Summary
Clovis Oncology Inc. netted $325mm through an upsized public offering of 3.9mm common shares (including the overallotment) at $88. (The company originally intended to raise $250mm from the sale.) Some of the proceeds will support marketing expenses for Rubraca (rucaparib) for ovarian cancer in the US (and in the EU, once approved there). Funds will also go towards ongoing development activities and potential in-licensing or acquisition of additional cancer projects.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Public offering nets $325mm for Clovis Oncology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice